FDA
-
-
-
-
-
-
-
Alpha Cognition appoints Bethany Sensenig to board of directors
-
-
-
-
-
-
-
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
-
-
-
-
-
-
-
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference
-
-
-
-
-
-
-
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
-
-
-
-
-
-
-
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
-
-
-
-
-
-
-
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
-
-
-
-
-
-
-
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

